|
| Press Releases |
|
 |
|
| Friday, March 19, 2021 |
|
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
| Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
| Friday, December 18, 2020 |
|
|
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: more info >> |
|
| Wednesday, October 14, 2020 |
|
|
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin |
Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau.
more info >> |
|
| Monday, August 17, 2020 |
|
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
| Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
| Wednesday, July 1, 2020 |
|
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
| Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
| Thursday, June 18, 2020 |
|
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
| Monday, April 27, 2020 |
|
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
| Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
| Monday, March 16, 2020 |
|
|
Hua Medicine Announces 2019 Annual Results |
| Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. more info >> |
|
| Friday, February 14, 2020 |
|
|
Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer |
| Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Concord New Energy Signs MOU with Bain Capital-Backed Bridge Data Centre
Mar 3, 2026 15:27 HKT/SGT
|
|
|
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
Mar 3, 2026 12:14 HKT/SGT
|
|
|
Affiliate of Pacific Avenue Capital Partners to Acquire Care.com from IAC
Mar 3, 2026 08:00 HKT/SGT
|
|
|
Lessn exceeds $100 million turnover on its payments orchestration platform
Mar 3, 2026 06:00 HKT/SGT
|
|
|
Graphene Manufacturing Group Ltd. Approves AU$1.4 Million Deployment: The Remaining Capital Needed for a Second Generation
Mar 3, 2026 04:59 HKT/SGT
|
|
|
Doubleview Gold Corp. Announces Positive Preliminary Economic Assessment for the Hat Project; Robust Base-Case Economics with Strategic Scandium Upside
Mar 3, 2026 00:59 HKT/SGT
|
|
|
With Step-Out Drilling Continuing, Radisson Demonstrates Meaningful Resource Growth at O'Brien with an Updated Mineral Resource Estimate
Mar 2, 2026 19:59 HKT/SGT
|
|
|
Lincotrade Unveils Freehold Residential Project, The Shang Residence, in Kuala Lumpur, Malaysia
Mar 2, 2026 19:54 HKT/SGT
|
|
|
Focus Graphite Officially Commences Government-Supported Thermal Purification Project to Establish Dual-Use Graphite Production in Canada
Mar 2, 2026 18:29 HKT/SGT
|
|
|
The HK International Diamond, Gem & Pearl Show opens today; The HK International Jewellery Show starts Wednesday
Mar 2, 2026 18:20 HKT/SGT
|
|
|
MHI and SoftBank Corp. Collaborate to Adapt AI-RAN Network Architecture for Edge Data Centers
Mar 2, 2026 19:13 JST
|
|
|
Exito Media Concepts Announces the 32nd Edition of the Manufacturing IT Summit - Thailand 2026
Mar 2, 2026 17:00 HKT/SGT
|
|
|
DOCOMO and NEC Launch Japan's First Commercial 5G Core on AWS, Built with World's First AI-automated Network Construction Technology
Mar 2, 2026 16:34 JST
|
|
|
AI Safety Asia Advances Crisis Diplomacy and Evidence-Based AI Governance at India AI Impact Summit 2026
Mar 2, 2026 15:15 HKT/SGT
|
|
|
Fujitsu supports sustainable growth for retailers with data and AI through Uvance for Retail
Mar 2, 2026 11:55 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
